ID   KPCI_HUMAN              Reviewed;         596 AA.
AC   P41743; D3DNQ4; Q8WW06;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2009, sequence version 2.
DT   10-MAY-2017, entry version 194.
DE   RecName: Full=Protein kinase C iota type;
DE            EC=2.7.11.13;
DE   AltName: Full=Atypical protein kinase C-lambda/iota;
DE            Short=PRKC-lambda/iota;
DE            Short=aPKC-lambda/iota;
DE   AltName: Full=nPKC-iota;
GN   Name=PRKCI; Synonyms=DXS1179E;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=8226978;
RA   Selbie L.A., Schmitz-Peiffer C., Sheng Y., Biden T.J.;
RT   "Molecular cloning and characterization of PKC iota, an atypical
RT   isoform of protein kinase C derived from insulin-secreting cells.";
RL   J. Biol. Chem. 268:24296-24302(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=7607695; DOI=10.1016/0888-7543(95)80190-W;
RA   Mazzarella R., Ciccodicola A., Esposito T., Arcucci A., Migliaccio C.,
RA   Jones C., Schlessinger D., D'Urso M., D'Esposito M.;
RT   "Human protein kinase C iota gene (PRKCI) is closely linked to the BTK
RT   gene in Xq21.3.";
RL   Genomics 26:629-631(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH SMG1, AND ENZYME REGULATION.
RX   PubMed=8524286; DOI=10.1128/MCB.16.1.105;
RA   Diaz-Meco M.T., Municio M.M., Sanchez P., Lozano J., Moscat J.;
RT   "Lambda-interacting protein, a novel protein that specifically
RT   interacts with the zinc finger domain of the atypical protein kinase C
RT   isotype lambda/iota and stimulates its kinase activity in vitro and in
RT   vivo.";
RL   Mol. Cell. Biol. 16:105-114(1996).
RN   [6]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=9346882; DOI=10.1074/jbc.272.44.27521;
RA   Murray N.R., Fields A.P.;
RT   "Atypical protein kinase C iota protects human leukemia cells against
RT   drug-induced apoptosis.";
RL   J. Biol. Chem. 272:27521-27524(1997).
RN   [7]
RP   INTERACTION WITH SQSTM1, AND SUBCELLULAR LOCATION.
RX   PubMed=9566925; DOI=10.1128/MCB.18.5.3069;
RA   Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.;
RT   "Localization of atypical protein kinase C isoforms into lysosome-
RT   targeted endosomes through interaction with p62.";
RL   Mol. Cell. Biol. 18:3069-3080(1998).
RN   [8]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=10467349; DOI=10.1038/sj.cdd.4400548;
RA   Wooten M.W., Seibenhener M.L., Zhou G., Vandenplas M.L., Tan T.H.;
RT   "Overexpression of atypical PKC in PC12 cells enhances NGF-
RT   responsiveness and survival through an NF-kappaB dependent pathway.";
RL   Cell Death Differ. 6:753-764(1999).
RN   [9]
RP   INTERACTION WITH SQSTM1 AND IKBKB, AND FUNCTION.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [10]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF LYS-274.
RX   PubMed=10906326; DOI=10.1074/jbc.M002742200;
RA   Spitaler M., Villunger A., Grunicke H., Uberall F.;
RT   "Unique structural and functional properties of the ATP-binding domain
RT   of atypical protein kinase C-iota.";
RL   J. Biol. Chem. 275:33289-33296(2000).
RN   [11]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=11042363; DOI=10.1016/S0169-328X(00)00187-X;
RA   Xie J., Guo Q., Zhu H., Wooten M.W., Mattson M.P.;
RT   "Protein kinase C iota protects neural cells against apoptosis induced
RT   by amyloid beta-peptide.";
RL   Brain Res. Mol. Brain Res. 82:107-113(2000).
RN   [12]
RP   INTERACTION WITH PARD6A; PARD6B AND PARD6G, AND SUBUNIT OF A COMPLEX
RP   CONTAINING PARD6B AND CDC42/RAC1.
RX   PubMed=11260256; DOI=10.1046/j.1365-2443.2001.00404.x;
RA   Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.;
RT   "Human homologues of the Caenorhabditis elegans cell polarity protein
RT   PAR6 as an adaptor that links the small GTPases Rac and Cdc42 to
RT   atypical protein kinase C.";
RL   Genes Cells 6:107-119(2001).
RN   [13]
RP   INTERACTION WITH PARD3 AND PARD6B IN THE TERNARY AKPC/PAR3/PAR6
RP   COMPLEX.
RX   PubMed=11257119; DOI=10.1083/jcb.152.6.1183;
RA   Suzuki A., Yamanaka T., Hirose T., Manabe N., Mizuno K., Shimizu M.,
RA   Akimoto K., Izumi Y., Ohnishi T., Ohno S.;
RT   "Atypical protein kinase C is involved in the evolutionarily conserved
RT   par protein complex and plays a critical role in establishing
RT   epithelia-specific junctional structures.";
RL   J. Cell Biol. 152:1183-1196(2001).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH GAPDH.
RX   PubMed=11724794; DOI=10.1074/jbc.M109744200;
RA   Tisdale E.J.;
RT   "Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein
RT   kinase Ciota /lambda and plays a role in microtubule dynamics in the
RT   early secretory pathway.";
RL   J. Biol. Chem. 277:3334-3341(2002).
RN   [15]
RP   PHOSPHORYLATION AT TYR-265; TYR-280 AND TYR-334, AND MUTAGENESIS OF
RP   TYR-265; TYR-280 AND TYR-334.
RX   PubMed=11713277; DOI=10.1128/MCB.21.24.8414-8427.2001;
RA   Wooten M.W., Vandenplas M.L., Seibenhener M.L., Geetha T.,
RA   Diaz-Meco M.T.;
RT   "Nerve growth factor stimulates multisite tyrosine phosphorylation and
RT   activation of the atypical protein kinase C's via a src kinase
RT   pathway.";
RL   Mol. Cell. Biol. 21:8414-8427(2001).
RN   [16]
RP   INTERACTION WITH KPNB1, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   TYR-265, AND MUTAGENESIS OF TYR-265.
RX   PubMed=11891849; DOI=10.1002/jcb.10101.abs;
RA   White W.O., Seibenhener M.L., Wooten M.W.;
RT   "Phosphorylation of tyrosine 256 facilitates nuclear import of
RT   atypical protein kinase C.";
RL   J. Cell. Biochem. 85:42-53(2002).
RN   [17]
RP   INTERACTION WITH ADAP1.
RX   PubMed=12893243; DOI=10.1016/S0006-291X(03)01187-2;
RA   Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D.,
RA   Wakefield R.I.D., Johannes F.-J., Aitken A.;
RT   "Centaurin-alpha(1) associates with and is phosphorylated by isoforms
RT   of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 307:459-465(2003).
RN   [18]
RP   INTERACTION WITH PARD6B/PAR-6 AND LLGL1.
RX   PubMed=12725730; DOI=10.1016/S0960-9822(03)00244-6;
RA   Yamanaka T., Horikoshi Y., Sugiyama Y., Ishiyama C., Suzuki A.,
RA   Hirose T., Iwamatsu A., Shinohara A., Ohno S.;
RT   "Mammalian Lgl forms a protein complex with PAR-6 and aPKC
RT   independently of PAR-3 to regulate epithelial cell polarity.";
RL   Curr. Biol. 13:734-743(2003).
RN   [19]
RP   FUNCTION.
RX   PubMed=12871960; DOI=10.1074/jbc.M305381200;
RA   Tisdale E.J., Wang J., Silver R.B., Artalejo C.R.;
RT   "Atypical protein kinase C plays a critical role in protein transport
RT   from pre-Golgi intermediates.";
RL   J. Biol. Chem. 278:38015-38021(2003).
RN   [20]
RP   INTERACTION WITH RAB2A.
RX   PubMed=14570876; DOI=10.1074/jbc.M309343200;
RA   Tisdale E.J.;
RT   "Rab2 interacts directly with atypical protein kinase C (aPKC)
RT   iota/lambda and inhibits aPKCiota/lambda-dependent glyceraldehyde-3-
RT   phosphate dehydrogenase phosphorylation.";
RL   J. Biol. Chem. 278:52524-52530(2003).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF IRAK1.
RX   PubMed=14684752; DOI=10.1074/jbc.C300431200;
RA   Mamidipudi V., Lin C., Seibenhener M.L., Wooten M.W.;
RT   "Regulation of interleukin receptor-associated kinase (IRAK)
RT   phosphorylation and signaling by iota protein kinase C.";
RL   J. Biol. Chem. 279:4161-4165(2004).
RN   [22]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15994303; DOI=10.1074/jbc.M505402200;
RA   Regala R.P., Weems C., Jamieson L., Copland J.A., Thompson E.A.,
RA   Fields A.P.;
RT   "Atypical protein kinase Ciota plays a critical role in human lung
RT   cancer cell growth and tumorigenicity.";
RL   J. Biol. Chem. 280:31109-31115(2005).
RN   [23]
RP   INTERACTION WITH CDK7, AND SUBCELLULAR LOCATION.
RX   PubMed=15695176; DOI=10.1016/j.tice.2004.10.004;
RA   Bicaku E., Patel R., Acevedo-Duncan M.;
RT   "Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-
RT   iota in human glioma cells.";
RL   Tissue Cell 37:53-58(2005).
RN   [24]
RP   INTERACTION WITH WDFY2.
RX   PubMed=16792529; DOI=10.1042/BJ20060511;
RA   Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M.,
RA   Bosse M., Zimmermann S., Frey A.D., Caelers A., Bachmann A.S.,
RA   Moelling K.;
RT   "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda.";
RL   Biochem. J. 399:9-20(2006).
RN   [25]
RP   INTERACTION WITH RAB2A AND GADPH, PHOSPHORYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16452474; DOI=10.1074/jbc.M513031200;
RA   Tisdale E.J., Artalejo C.R.;
RT   "Src-dependent protein kinase C iota/lambda (aPKCiota/lambda) tyrosine
RT   phosphorylation is required for aPKCiota/lambda association with Rab2
RT   and glyceraldehyde-3-phosphate dehydrogenase on pre-Golgi
RT   intermediates.";
RL   J. Biol. Chem. 281:8436-8442(2006).
RN   [26]
RP   INTERACTION WITH VAMP2.
RX   PubMed=17313651; DOI=10.1111/j.1742-4658.2007.05702.x;
RA   Fritzius T., Frey A.D., Schweneker M., Mayer D., Moelling K.;
RT   "WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein
RT   kinase Czeta.";
RL   FEBS J. 274:1552-1566(2007).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF EZR.
RX   PubMed=18270268; DOI=10.1242/jcs.016246;
RA   Wald F.A., Oriolo A.S., Mashukova A., Fregien N.L., Langshaw A.H.,
RA   Salas P.J.;
RT   "Atypical protein kinase C (iota) activates ezrin in the apical domain
RT   of intestinal epithelial cells.";
RL   J. Cell Sci. 121:644-654(2008).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=19327373; DOI=10.1016/j.mvr.2009.01.014;
RA   Staiger K., Schatz U., Staiger H., Weyrich P., Haas C., Guirguis A.,
RA   Machicao F., Haering H.U., Kellerer M.;
RT   "Protein kinase C iota mediates lipid-induced apoptosis of human
RT   coronary artery endothelial cells.";
RL   Microvasc. Res. 78:40-44(2009).
RN   [32]
RP   INTERACTION WITH ECT2 AND PARD6A, AND MUTAGENESIS OF ASP-72.
RX   PubMed=19617897; DOI=10.1038/onc.2009.217;
RA   Justilien V., Fields A.P.;
RT   "Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and
RT   cellular transformation.";
RL   Oncogene 28:3597-3607(2009).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT PRO-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT THR-3; SER-7; SER-8 AND THR-9, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   FUNCTION IN PHOSPHORYLATION OF BAD.
RX   PubMed=21419810; DOI=10.1016/j.bbamcr.2011.03.007;
RA   Desai S., Pillai P., Win-Piazza H., Acevedo-Duncan M.;
RT   "PKC-? promotes glioblastoma cell survival by phosphorylating and
RT   inhibiting BAD through a phosphatidylinositol 3-kinase pathway.";
RL   Biochim. Biophys. Acta 1813:1190-1197(2011).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF ECT2.
RX   PubMed=21189248; DOI=10.1074/jbc.M110.196113;
RA   Justilien V., Jameison L., Der C.J., Rossman K.L., Fields A.P.;
RT   "Oncogenic activity of Ect2 is regulated through protein kinase C
RT   iota-mediated phosphorylation.";
RL   J. Biol. Chem. 286:8149-8157(2011).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-564, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-564, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [41]
RP   STRUCTURE BY NMR OF 25-108, INTERACTION WITH SQSTM1 AND MAP2K5, AND
RP   MUTAGENESIS OF LYS-29 AND ASP-72.
RX   PubMed=15143057; DOI=10.1074/jbc.M403092200;
RA   Hirano Y., Yoshinaga S., Ogura K., Yokochi M., Noda Y., Sumimoto H.,
RA   Inagaki F.;
RT   "Solution structure of atypical protein kinase C PB1 domain and its
RT   mode of interaction with ZIP/p62 and MEK5.";
RL   J. Biol. Chem. 279:31883-31890(2004).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 25-108 IN COMPLEX WITH
RP   PARD6A, AND MUTAGENESIS OF ASP-72; GLU-85 AND ARG-91.
RX   PubMed=15590654; DOI=10.1074/jbc.M409823200;
RA   Hirano Y., Yoshinaga S., Takeya R., Suzuki N.N., Horiuchi M.,
RA   Kohjima M., Sumimoto H., Inagaki F.;
RT   "Structure of a cell polarity regulator, a complex between atypical
RT   PKC and Par6 PB1 domains.";
RL   J. Biol. Chem. 280:9653-9661(2005).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 233-596, IDENTIFICATION BY
RP   MASS SPECTROMETRY, AND PHOSPHORYLATION AT THR-412 AND THR-564.
RX   PubMed=16125198; DOI=10.1016/j.jmb.2005.07.060;
RA   Messerschmidt A., Macieira S., Velarde M., Baedeker M., Benda C.,
RA   Jestel A., Brandstetter H., Neuefeind T., Blaesse M.;
RT   "Crystal structure of the catalytic domain of human atypical protein
RT   kinase C-iota reveals interaction mode of phosphorylation site in turn
RT   motif.";
RL   J. Mol. Biol. 352:918-931(2005).
RN   [44]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-118 AND CYS-130.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium- and diacylglycerol-independent serine/
CC       threonine-protein kinase that plays a general protective role
CC       against apoptotic stimuli, is involved in NF-kappa-B activation,
CC       cell survival, differentiation and polarity, and contributes to
CC       the regulation of microtubule dynamics in the early secretory
CC       pathway. Is necessary for BCR-ABL oncogene-mediated resistance to
CC       apoptotic drug in leukemia cells, protecting leukemia cells
CC       against drug-induced apoptosis. In cultured neurons, prevents
CC       amyloid beta protein-induced apoptosis by interrupting cell death
CC       process at a very early step. In glioblastoma cells, may function
CC       downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in
CC       the promotion of cell survival by phosphorylating and inhibiting
CC       the pro-apoptotic factor BAD. Can form a protein complex in non-
CC       small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and
CC       regulate ECT2 oncogenic activity by phosphorylation, which in turn
CC       promotes transformed growth and invasion. In response to nerve
CC       growth factor (NGF), acts downstream of SRC to phosphorylate and
CC       activate IRAK1, allowing the subsequent activation of NF-kappa-B
CC       and neuronal cell survival. Functions in the organization of the
CC       apical domain in epithelial cells by phosphorylating EZR. This
CC       step is crucial for activation and normal distribution of EZR at
CC       the early stages of intestinal epithelial cell differentiation.
CC       Forms a protein complex with LLGL1 and PARD6B independently of
CC       PARD3 to regulate epithelial cell polarity. Plays a role in
CC       microtubule dynamics in the early secretory pathway through
CC       interaction with RAB2A and GAPDH and recruitment to vesicular
CC       tubular clusters (VTCs). In human coronary artery endothelial
CC       cells (HCAEC), is activated by saturated fatty acids and mediates
CC       lipid-induced apoptosis. {ECO:0000269|PubMed:10356400,
CC       ECO:0000269|PubMed:10467349, ECO:0000269|PubMed:10906326,
CC       ECO:0000269|PubMed:11042363, ECO:0000269|PubMed:11724794,
CC       ECO:0000269|PubMed:12871960, ECO:0000269|PubMed:14684752,
CC       ECO:0000269|PubMed:15994303, ECO:0000269|PubMed:18270268,
CC       ECO:0000269|PubMed:19327373, ECO:0000269|PubMed:21189248,
CC       ECO:0000269|PubMed:21419810, ECO:0000269|PubMed:8226978,
CC       ECO:0000269|PubMed:9346882}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit an
CC       elevated basal enzymatic activity (that may be due to the
CC       interaction with SMG1 or SQSTM1) and are not regulated by
CC       diacylglycerol, phosphatidylserine, phorbol esters or calcium
CC       ions. Two specific sites, Thr-412 (activation loop of the kinase
CC       domain) and Thr-564 (turn motif), need to be phosphorylated for
CC       its full activation (By similarity). Might also be a target for
CC       novel lipid activators that are elevated during nutrient-
CC       stimulated insulin secretion. {ECO:0000250,
CC       ECO:0000269|PubMed:8524286}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=13.5 uM for ATP (for recombinant purified PRKCI)
CC         {ECO:0000269|PubMed:10906326};
CC         Vmax=7.4 pmol/min/mg enzyme {ECO:0000269|PubMed:10906326};
CC   -!- SUBUNIT: Forms a complex with SQSTM1 and MP2K5 (By similarity).
CC       Interacts directly with SQSTM1 (Probable). Interacts with IKBKB.
CC       Interacts with PARD6A, PARD6B and PARD6G. Part of a quaternary
CC       complex containing aPKC, PARD3, a PARD6 protein (PARD6A, PARD6B or
CC       PARD6G) and a GTPase protein (CDC42 or RAC1). Part of a complex
CC       with LLGL1 and PARD6B. Interacts with ADAP1/CENTA1. Interaction
CC       with SMG1, through the ZN-finger domain, activates the kinase
CC       activity. Interacts with CDK7. Forms a complex with RAB2A and
CC       GAPDH involved in recruitment onto the membrane of vesicular
CC       tubular clusters (VTCs). Interacts with ECT2 ('Thr-359'
CC       phosphorylated form). Interacts with VAMP2 (PubMed:17313651).
CC       Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529).
CC       {ECO:0000250|UniProtKB:Q62074, ECO:0000269|PubMed:10356400,
CC       ECO:0000269|PubMed:11257119, ECO:0000269|PubMed:11260256,
CC       ECO:0000269|PubMed:11724794, ECO:0000269|PubMed:11891849,
CC       ECO:0000269|PubMed:12725730, ECO:0000269|PubMed:12893243,
CC       ECO:0000269|PubMed:14570876, ECO:0000269|PubMed:15143057,
CC       ECO:0000269|PubMed:15590654, ECO:0000269|PubMed:15695176,
CC       ECO:0000269|PubMed:16452474, ECO:0000269|PubMed:16792529,
CC       ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:19617897,
CC       ECO:0000269|PubMed:8524286, ECO:0000269|PubMed:9566925,
CC       ECO:0000305}.
CC   -!- INTERACTION:
CC       P60953:CDC42; NbExp=5; IntAct=EBI-286199, EBI-81752;
CC       P78545:ELF3; NbExp=2; IntAct=EBI-286199, EBI-1057285;
CC       Q96L34:MARK4; NbExp=2; IntAct=EBI-286199, EBI-302319;
CC       Q8TEW0:PARD3; NbExp=3; IntAct=EBI-286199, EBI-81968;
CC       Q9NPB6:PARD6A; NbExp=12; IntAct=EBI-286199, EBI-81876;
CC       Q9NPB6-2:PARD6A; NbExp=4; IntAct=EBI-286199, EBI-10693102;
CC       Q9BYG5:PARD6B; NbExp=15; IntAct=EBI-286199, EBI-295391;
CC       Q9BYG4:PARD6G; NbExp=5; IntAct=EBI-286199, EBI-295417;
CC       Q8ND90:PNMA1; NbExp=2; IntAct=EBI-286199, EBI-302345;
CC       Q05513:PRKCZ; NbExp=4; IntAct=EBI-286199, EBI-295351;
CC       P63000:RAC1; NbExp=3; IntAct=EBI-286199, EBI-413628;
CC       P48431:SOX2; NbExp=2; IntAct=EBI-286199, EBI-6124081;
CC       Q13501:SQSTM1; NbExp=7; IntAct=EBI-286199, EBI-307104;
CC       Q04917:YWHAH; NbExp=3; IntAct=EBI-286199, EBI-306940;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11891849,
CC       ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:9566925}. Membrane
CC       {ECO:0000269|PubMed:16452474}. Endosome
CC       {ECO:0000269|PubMed:9566925}. Nucleus
CC       {ECO:0000269|PubMed:11891849, ECO:0000269|PubMed:15695176}.
CC       Note=Transported into the endosome through interaction with
CC       SQSTM1/p62. After phosphorylation by SRC, transported into the
CC       nucleus through interaction with KPNB1. Colocalizes with CDK7 in
CC       the cytoplasm and nucleus. Transported to vesicular tubular
CC       clusters (VTCs) through interaction with RAB2A.
CC       {ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:9566925}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in lung and brain, but
CC       also expressed at lower levels in many tissues including
CC       pancreatic islets. Highly expressed in non-small cell lung
CC       cancers. {ECO:0000269|PubMed:15994303, ECO:0000269|PubMed:7607695,
CC       ECO:0000269|PubMed:8226978}.
CC   -!- DOMAIN: The PB1 domain mediates interaction with SQSTM1.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The C1 zinc finger does not bind diacylglycerol (DAG).
CC   -!- DOMAIN: The pseudosubstrate motif resembles the sequence around
CC       sites phosphorylated on target proteins, except the presence of a
CC       non-phosphorylatable residue in place of Ser, it modulates
CC       activity by competing with substrates. {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Thr-412 in the activation loop is not
CC       mandatory for activation (By similarity). Upon neuronal growth
CC       factor (NGF) stimulation, phosphorylated by SRC at Tyr-265, Tyr-
CC       280 and Tyr-334. Phosphorylation at Tyr-265 facilitates binding to
CC       KPNB1/importin-beta regulating entry of PRKCI into the nucleus.
CC       Phosphorylation on Tyr-334 is important for NF-kappa-B
CC       stimulation. {ECO:0000250, ECO:0000269|PubMed:11713277,
CC       ECO:0000269|PubMed:11891849, ECO:0000269|PubMed:16125198,
CC       ECO:0000269|PubMed:16452474}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA60171.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAB17011.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH22016.3; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKCIID41857ch3q26.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L18964; AAA60171.1; ALT_INIT; mRNA.
DR   EMBL; L33881; AAB17011.1; ALT_INIT; mRNA.
DR   EMBL; CH471052; EAW78513.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78515.1; -; Genomic_DNA.
DR   EMBL; BC022016; AAH22016.3; ALT_INIT; mRNA.
DR   CCDS; CCDS3212.2; -.
DR   PIR; A49509; A49509.
DR   RefSeq; NP_002731.4; NM_002740.5.
DR   UniGene; Hs.478199; -.
DR   PDB; 1VD2; NMR; -; A=25-108.
DR   PDB; 1WMH; X-ray; 1.50 A; A=25-108.
DR   PDB; 1ZRZ; X-ray; 3.00 A; A=233-596.
DR   PDB; 3A8W; X-ray; 2.10 A; A/B=249-588.
DR   PDB; 3A8X; X-ray; 2.00 A; A/B=249-588.
DR   PDB; 3ZH8; X-ray; 2.74 A; A/B/C=248-594.
DR   PDB; 5LI1; X-ray; 2.00 A; A=248-596.
DR   PDB; 5LI9; X-ray; 1.79 A; A=248-596.
DR   PDB; 5LIH; X-ray; 3.25 A; A/B=248-596.
DR   PDBsum; 1VD2; -.
DR   PDBsum; 1WMH; -.
DR   PDBsum; 1ZRZ; -.
DR   PDBsum; 3A8W; -.
DR   PDBsum; 3A8X; -.
DR   PDBsum; 3ZH8; -.
DR   PDBsum; 5LI1; -.
DR   PDBsum; 5LI9; -.
DR   PDBsum; 5LIH; -.
DR   ProteinModelPortal; P41743; -.
DR   SMR; P41743; -.
DR   BioGrid; 111570; 82.
DR   DIP; DIP-31311N; -.
DR   IntAct; P41743; 55.
DR   MINT; MINT-5004219; -.
DR   STRING; 9606.ENSP00000295797; -.
DR   BindingDB; P41743; -.
DR   ChEMBL; CHEMBL2598; -.
DR   DrugBank; DB03777; Rbt205 Inhibitor.
DR   DrugBank; DB00675; Tamoxifen.
DR   GuidetoPHARMACOLOGY; 1490; -.
DR   iPTMnet; P41743; -.
DR   PhosphoSitePlus; P41743; -.
DR   BioMuta; PRKCI; -.
DR   DMDM; 239938658; -.
DR   EPD; P41743; -.
DR   MaxQB; P41743; -.
DR   PaxDb; P41743; -.
DR   PeptideAtlas; P41743; -.
DR   PRIDE; P41743; -.
DR   DNASU; 5584; -.
DR   Ensembl; ENST00000295797; ENSP00000295797; ENSG00000163558.
DR   GeneID; 5584; -.
DR   KEGG; hsa:5584; -.
DR   UCSC; uc003fgs.3; human.
DR   CTD; 5584; -.
DR   DisGeNET; 5584; -.
DR   GeneCards; PRKCI; -.
DR   HGNC; HGNC:9404; PRKCI.
DR   HPA; HPA026574; -.
DR   HPA; HPA038635; -.
DR   MIM; 600539; gene.
DR   neXtProt; NX_P41743; -.
DR   OpenTargets; ENSG00000163558; -.
DR   PharmGKB; PA33768; -.
DR   eggNOG; KOG0695; Eukaryota.
DR   eggNOG; ENOG410ZMG2; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P41743; -.
DR   KO; K06069; -.
DR   OMA; KLVTVEC; -.
DR   OrthoDB; EOG091G03Q9; -.
DR   PhylomeDB; P41743; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-209543; p75NTR recruits signalling complexes.
DR   Reactome; R-HSA-420029; Tight junction interactions.
DR   SignaLink; P41743; -.
DR   SIGNOR; P41743; -.
DR   ChiTaRS; PRKCI; human.
DR   EvolutionaryTrace; P41743; -.
DR   GeneWiki; PRKCI; -.
DR   GenomeRNAi; 5584; -.
DR   PRO; PR:P41743; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000163558; -.
DR   CleanEx; HS_PRKCI; -.
DR   Genevisible; P41743; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl.
DR   GO; GO:0031252; C:cell leading edge; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:GOC.
DR   GO; GO:0045171; C:intercellular bridge; IDA:HPA.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; TAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005543; F:phospholipid binding; IDA:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; ISS:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007015; P:actin filament organization; IEA:Ensembl.
DR   GO; GO:0070830; P:bicellular tight junction assembly; TAS:Reactome.
DR   GO; GO:0016477; P:cell migration; IEA:Ensembl.
DR   GO; GO:0045216; P:cell-cell junction organization; IMP:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:BHF-UCL.
DR   GO; GO:0007010; P:cytoskeleton organization; NAS:UniProtKB.
DR   GO; GO:0035089; P:establishment of apical/basal cell polarity; IEA:Ensembl.
DR   GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; TAS:UniProtKB.
DR   GO; GO:0042462; P:eye photoreceptor cell development; IEA:Ensembl.
DR   GO; GO:0048194; P:Golgi vesicle budding; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0061024; P:membrane organization; NAS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:WormBase.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISS:BHF-UCL.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006612; P:protein targeting to membrane; NAS:UniProtKB.
DR   GO; GO:0070555; P:response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0046903; P:secretion; NAS:UniProtKB.
DR   GO; GO:0016192; P:vesicle-mediated transport; TAS:UniProtKB.
DR   CDD; cd00029; C1; 1.
DR   CDD; cd05618; STKc_aPKC_iota; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR034661; aPKC_iota.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000270; PB1_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR012233; PKC.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00564; PB1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000554; PKC_zeta; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00666; PB1; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS51745; PB1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Cytoplasm;
KW   Endosome; Kinase; Membrane; Metal-binding; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Tumor suppressor; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:20068231}.
FT   CHAIN         2    596       Protein kinase C iota type.
FT                                /FTId=PRO_0000055710.
FT   DOMAIN       25    108       PB1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01081}.
FT   DOMAIN      254    522       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      523    594       AGC-kinase C-terminal.
FT   ZN_FING     140    190       Phorbol-ester/DAG-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     260    268       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        2    253       Regulatory domain.
FT   REGION        2     28       Required for interaction with RAB2.
FT   REGION       72     91       Interaction with PARD6A.
FT   MOTIF       125    134       Pseudosubstrate. {ECO:0000250}.
FT   ACT_SITE    378    378       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     283    283       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylproline.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES       3      3       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES       7      7       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES       8      8       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES       9      9       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     265    265       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:11713277,
FT                                ECO:0000269|PubMed:11891849}.
FT   MOD_RES     280    280       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:11713277}.
FT   MOD_RES     334    334       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:11713277}.
FT   MOD_RES     412    412       Phosphothreonine; by PDPK1.
FT                                {ECO:0000305|PubMed:16125198}.
FT   MOD_RES     564    564       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:16125198}.
FT   VARIANT     118    118       P -> L (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042322.
FT   VARIANT     130    130       R -> C (in dbSNP:rs56154494).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042323.
FT   MUTAGEN      29     29       K->A: No effect on interaction with
FT                                SQSTM1. {ECO:0000269|PubMed:15143057}.
FT   MUTAGEN      72     72       D->A: Loss of interaction with ECT2,
FT                                PARD6A and with SQSTM1.
FT                                {ECO:0000269|PubMed:15143057,
FT                                ECO:0000269|PubMed:15590654,
FT                                ECO:0000269|PubMed:19617897}.
FT   MUTAGEN      85     85       E->A: Slight decrease of interaction with
FT                                PARD6A. Loss of interaction with PARD6A;
FT                                when associated with A-91.
FT                                {ECO:0000269|PubMed:15590654}.
FT   MUTAGEN      91     91       R->A: Slight decrease of interaction with
FT                                PARD6A. Loss of interaction with PARD6A;
FT                                when associated with A-85.
FT                                {ECO:0000269|PubMed:15590654}.
FT   MUTAGEN     265    265       Y->F: No effect on the SRC-mediated
FT                                phosphorylation state. No effect on SRC-
FT                                induced enzyme activity. Little effect on
FT                                TRAF6-mediated activation of NF-kappa-B.
FT                                Decreased binding to KPNB1/importin-beta.
FT                                {ECO:0000269|PubMed:11713277,
FT                                ECO:0000269|PubMed:11891849}.
FT   MUTAGEN     274    274       K->R: No effect on activity.
FT                                {ECO:0000269|PubMed:10906326}.
FT   MUTAGEN     274    274       K->W: Abolishes activity.
FT                                {ECO:0000269|PubMed:10906326}.
FT   MUTAGEN     280    280       Y->F: No effect on the SRC-mediated
FT                                phosphorylation state. No effect on SRC-
FT                                induced enzyme activity. No effect on
FT                                TRAF6-mediated activation of NF-kappa-B.
FT                                {ECO:0000269|PubMed:11713277}.
FT   MUTAGEN     334    334       Y->F: No effect on the SRC-mediated
FT                                phosphorylation state. Significant
FT                                reduction of SRC-induced enzyme activity.
FT                                Greatly reduced TRAF6-mediated activation
FT                                of NF-kappa-B. Reduces NGF-dependent cell
FT                                survival. {ECO:0000269|PubMed:11713277}.
FT   CONFLICT    485    485       L -> M (in Ref. 4; AAH22016).
FT                                {ECO:0000305}.
FT   CONFLICT    508    508       H -> L (in Ref. 4; AAH22016).
FT                                {ECO:0000305}.
FT   CONFLICT    560    560       P -> R (in Ref. 4; AAH22016).
FT                                {ECO:0000305}.
FT   STRAND       26     32       {ECO:0000244|PDB:1WMH}.
FT   STRAND       35     41       {ECO:0000244|PDB:1WMH}.
FT   HELIX        47     57       {ECO:0000244|PDB:1WMH}.
FT   STRAND       67     71       {ECO:0000244|PDB:1WMH}.
FT   STRAND       73     75       {ECO:0000244|PDB:1VD2}.
FT   STRAND       77     79       {ECO:0000244|PDB:1WMH}.
FT   HELIX        83     95       {ECO:0000244|PDB:1WMH}.
FT   STRAND      101    106       {ECO:0000244|PDB:1WMH}.
FT   HELIX       251    253       {ECO:0000244|PDB:5LI9}.
FT   STRAND      254    262       {ECO:0000244|PDB:5LI9}.
FT   STRAND      264    273       {ECO:0000244|PDB:5LI9}.
FT   TURN        274    277       {ECO:0000244|PDB:3A8X}.
FT   STRAND      279    286       {ECO:0000244|PDB:5LI9}.
FT   HELIX       287    289       {ECO:0000244|PDB:5LI9}.
FT   HELIX       293    309       {ECO:0000244|PDB:5LI9}.
FT   STRAND      318    323       {ECO:0000244|PDB:5LI9}.
FT   STRAND      325    332       {ECO:0000244|PDB:5LI9}.
FT   HELIX       340    347       {ECO:0000244|PDB:5LI9}.
FT   HELIX       352    371       {ECO:0000244|PDB:5LI9}.
FT   HELIX       381    383       {ECO:0000244|PDB:5LI9}.
FT   STRAND      384    386       {ECO:0000244|PDB:5LI9}.
FT   STRAND      388    390       {ECO:0000244|PDB:3ZH8}.
FT   STRAND      392    394       {ECO:0000244|PDB:5LI9}.
FT   HELIX       397    399       {ECO:0000244|PDB:3A8X}.
FT   HELIX       417    419       {ECO:0000244|PDB:5LI9}.
FT   HELIX       422    425       {ECO:0000244|PDB:5LI9}.
FT   HELIX       433    448       {ECO:0000244|PDB:5LI9}.
FT   TURN        452    457       {ECO:0000244|PDB:3A8X}.
FT   HELIX       467    476       {ECO:0000244|PDB:5LI9}.
FT   HELIX       487    496       {ECO:0000244|PDB:5LI9}.
FT   TURN        501    503       {ECO:0000244|PDB:5LI9}.
FT   TURN        505    507       {ECO:0000244|PDB:1ZRZ}.
FT   TURN        509    511       {ECO:0000244|PDB:5LI9}.
FT   HELIX       512    517       {ECO:0000244|PDB:5LI9}.
FT   HELIX       520    522       {ECO:0000244|PDB:5LI9}.
FT   HELIX       527    531       {ECO:0000244|PDB:5LI9}.
FT   TURN        545    547       {ECO:0000244|PDB:5LI9}.
FT   HELIX       549    551       {ECO:0000244|PDB:3A8X}.
FT   HELIX       554    557       {ECO:0000244|PDB:5LI9}.
FT   HELIX       568    571       {ECO:0000244|PDB:5LI9}.
FT   HELIX       576    579       {ECO:0000244|PDB:5LI9}.
SQ   SEQUENCE   596 AA;  68262 MW;  1E3F8C1D4BFC734F CRC64;
     MPTQRDSSTM SHTVAGGGSG DHSHQVRVKA YYRGDIMITH FEPSISFEGL CNEVRDMCSF
     DNEQLFTMKW IDEEGDPCTV SSQLELEEAF RLYELNKDSE LLIHVFPCVP ERPGMPCPGE
     DKSIYRRGAR RWRKLYCANG HTFQAKRFNR RAHCAICTDR IWGLGRQGYK CINCKLLVHK
     KCHKLVTIEC GRHSLPQEPV MPMDQSSMHS DHAQTVIPYN PSSHESLDQV GEEKEAMNTR
     ESGKASSSLG LQDFDLLRVI GRGSYAKVLL VRLKKTDRIY AMKVVKKELV NDDEDIDWVQ
     TEKHVFEQAS NHPFLVGLHS CFQTESRLFF VIEYVNGGDL MFHMQRQRKL PEEHARFYSA
     EISLALNYLH ERGIIYRDLK LDNVLLDSEG HIKLTDYGMC KEGLRPGDTT STFCGTPNYI
     APEILRGEDY GFSVDWWALG VLMFEMMAGR SPFDIVGSSD NPDQNTEDYL FQVILEKQIR
     IPRSLSVKAA SVLKSFLNKD PKERLGCHPQ TGFADIQGHP FFRNVDWDMM EQKQVVPPFK
     PNISGEFGLD NFDSQFTNEP VQLTPDDDDI VRKIDQSEFE GFEYINPLLM SAEECV
//
